FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977860210> ?p ?o ?g. }

• W2977860210 endingPage "89" @default.
• W2977860210 startingPage "82" @default.
• W2977860210 abstract "Background: Eribulin provided significant overall survival (OS) benefit in heavily pretreated advanced breast cancer patients in the EMBRACE trial. We investigated the use of eribulin in daily clinical practice, the relative effectiveness of eribulin versus non-eribulin chemotherapy, and the safety of eribulin in real-world patients included in the SOutheast Netherlands Advanced BREast cancer (SONABRE) registry.Material and methods: Patients treated with eribulin and eligible patients for eribulin who received a different chemotherapy (i.e., non-eribulin group) in ten hospitals in 2013–2017 were included. A multivariate matching algorithm was applied to correct for differences in baseline characteristics between the groups, including the number of previous treatment lines. Progression-free survival (PFS) and OS of eribulin were compared with the matched non-eribulin group through Kaplan-Meier curves and multivariate Cox proportional hazard models. The occurrence of dose delay and reduction was described.Results: Forty-five patients received eribulin according to its registration criteria and 74 patients were eligible for eribulin but received non-eribulin chemotherapy. Matching increased the similarity in baseline characteristics between the eribulin and non-eribulin groups. Median PFS was 3.5 months (95% confidence interval (CI): 2.7–5.5) in the eribulin group and 3.2 months (95% CI: 2.0–4.8) in the matched non-eribulin group (adjusted hazard ratio (HR): 0.83, 95% CI: 0.49–1.38). Median OS was 5.9 months (95% CI: 4.6–11.0) and 5.2 months (95% CI: 4.6–9.5) in the eribulin and non-eribulin groups, respectively (adjusted HR: 0.66, 95% CI: 0.38–1.13). Dose delay or reduction occurred in 14 patients (31%) receiving eribulin.Conclusions: No difference in PFS and OS was observed between eribulin and non-eribulin treated patients. Eribulin had a manageable toxicity profile." @default.
• W2977860210 created "2019-10-10" @default.
• W2977860210 creator A5010033480 @default.
• W2977860210 creator A5018595809 @default.
• W2977860210 creator A5020062116 @default.
• W2977860210 creator A5020911916 @default.
• W2977860210 creator A5021404933 @default.
• W2977860210 creator A5023734176 @default.
• W2977860210 creator A5027402633 @default.
• W2977860210 creator A5031023319 @default.
• W2977860210 creator A5031537356 @default.
• W2977860210 creator A5056300643 @default.
• W2977860210 creator A5057952498 @default.
• W2977860210 creator A5063711825 @default.
• W2977860210 creator A5064077142 @default.
• W2977860210 creator A5065740152 @default.
• W2977860210 creator A5065928405 @default.
• W2977860210 creator A5081933592 @default.
• W2977860210 date "2019-10-04" @default.
• W2977860210 modified "2023-10-06" @default.
• W2977860210 title "The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry" @default.
• W2977860210 cites W1904541254 @default.
• W2977860210 cites W2016390816 @default.
• W2977860210 cites W2105505806 @default.
• W2977860210 cites W2113498827 @default.
• W2977860210 cites W2127152525 @default.
• W2977860210 cites W2136970657 @default.
• W2977860210 cites W2137545466 @default.
• W2977860210 cites W2147167134 @default.
• W2977860210 cites W2151232694 @default.
• W2977860210 cites W2153610005 @default.
• W2977860210 cites W2155163959 @default.
• W2977860210 cites W2156513436 @default.
• W2977860210 cites W2166780089 @default.
• W2977860210 cites W2254119765 @default.
• W2977860210 cites W2339406321 @default.
• W2977860210 cites W2592985951 @default.
• W2977860210 cites W2613430271 @default.
• W2977860210 cites W2779086608 @default.
• W2977860210 cites W2790279948 @default.
• W2977860210 cites W2885034495 @default.
• W2977860210 cites W2899901637 @default.
• W2977860210 cites W2945716039 @default.
• W2977860210 doi "https://doi.org/10.1080/0284186x.2019.1670356" @default.
• W2977860210 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31583931" @default.
• W2977860210 hasPublicationYear "2019" @default.
• W2977860210 type Work @default.
• W2977860210 sameAs 2977860210 @default.
• W2977860210 citedByCount "5" @default.
• W2977860210 countsByYear W29778602102020 @default.
• W2977860210 countsByYear W29778602102021 @default.
• W2977860210 countsByYear W29778602102022 @default.
• W2977860210 countsByYear W29778602102023 @default.
• W2977860210 crossrefType "journal-article" @default.
• W2977860210 hasAuthorship W2977860210A5010033480 @default.
• W2977860210 hasAuthorship W2977860210A5018595809 @default.
• W2977860210 hasAuthorship W2977860210A5020062116 @default.
• W2977860210 hasAuthorship W2977860210A5020911916 @default.
• W2977860210 hasAuthorship W2977860210A5021404933 @default.
• W2977860210 hasAuthorship W2977860210A5023734176 @default.
• W2977860210 hasAuthorship W2977860210A5027402633 @default.
• W2977860210 hasAuthorship W2977860210A5031023319 @default.
• W2977860210 hasAuthorship W2977860210A5031537356 @default.
• W2977860210 hasAuthorship W2977860210A5056300643 @default.
• W2977860210 hasAuthorship W2977860210A5057952498 @default.
• W2977860210 hasAuthorship W2977860210A5063711825 @default.
• W2977860210 hasAuthorship W2977860210A5064077142 @default.
• W2977860210 hasAuthorship W2977860210A5065740152 @default.
• W2977860210 hasAuthorship W2977860210A5065928405 @default.
• W2977860210 hasAuthorship W2977860210A5081933592 @default.
• W2977860210 hasBestOaLocation W29778602101 @default.
• W2977860210 hasConcept C121608353 @default.
• W2977860210 hasConcept C126322002 @default.
• W2977860210 hasConcept C143998085 @default.
• W2977860210 hasConcept C207103383 @default.
• W2977860210 hasConcept C2775930923 @default.
• W2977860210 hasConcept C2776387010 @default.
• W2977860210 hasConcept C2776694085 @default.
• W2977860210 hasConcept C44249647 @default.
• W2977860210 hasConcept C50382708 @default.
• W2977860210 hasConcept C530470458 @default.
• W2977860210 hasConcept C71924100 @default.
• W2977860210 hasConceptScore W2977860210C121608353 @default.
• W2977860210 hasConceptScore W2977860210C126322002 @default.
• W2977860210 hasConceptScore W2977860210C143998085 @default.
• W2977860210 hasConceptScore W2977860210C207103383 @default.
• W2977860210 hasConceptScore W2977860210C2775930923 @default.
• W2977860210 hasConceptScore W2977860210C2776387010 @default.
• W2977860210 hasConceptScore W2977860210C2776694085 @default.
• W2977860210 hasConceptScore W2977860210C44249647 @default.
• W2977860210 hasConceptScore W2977860210C50382708 @default.
• W2977860210 hasConceptScore W2977860210C530470458 @default.
• W2977860210 hasConceptScore W2977860210C71924100 @default.
• W2977860210 hasIssue "1" @default.
• W2977860210 hasLocation W29778602101 @default.
• W2977860210 hasLocation W29778602102 @default.
• W2977860210 hasOpenAccess W2977860210 @default.
• W2977860210 hasPrimaryLocation W29778602101 @default.

• next